心筋梗塞治療薬の市場規模、シェア、成長分析、治療タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、地域別-産業予測、2025～2032年

心筋梗塞（MI）治療の世界市場規模は2023年に217億5,000万米ドルと評価され、2024年の227億3,000万米ドルから2032年には323億2,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは4.5%で成長する展望です。

心筋梗塞（MI）治療市場は、心臓発作の主要原因である冠動脈疾患の罹患率の上昇を主要要因として、大きな成長が見込まれています。年間約1,730万人が心臓病で死亡しており、効果的な治療オプションの緊急性はかつてないほど高まっています。高齢化、肥満率の増加、糖尿病や高血圧などの慢性疾患といった要因が、この増加の一因となっています。さらに、食生活の乱れや薬剤乱用などのライフスタイルの選択も心筋梗塞のリスクを高めています。さらに、正確な閉塞の検出や個別化治療アプローチのための革新的な方法が期待される技術の進歩も市場を後押ししています。効果的な治療法が普及するにつれ、心筋梗塞治療市場は拡大し、利害関係者に有利な機会をもたらすと期待されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要市場の考察

• 重要成功要因
• 競合の程度
• 主要投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• 規制分析
• 特許分析
• ケーススタディ

治療タイプによる世界の心筋梗塞（MI）治療市場規模&CAGR（2025～2032年）

• 市場概要
• 血栓溶解
  • ストレプトキナーゼ
  • 組み換え組織プラスミノーゲン活性化因子（rtPA）
• 一次経皮的冠動脈インターベンション（PCI）
  • バルーン血管形成術
  • ステント留置術（薬剤溶出ステントベアメタルステント）
• 冠動脈バイパス移植術（CABG）
• 薬剤（手術または介入療法の前後に使用される）
• その他の新たな治療法

薬剤クラスによる世界の心筋梗塞（MI）治療市場規模&CAGR（2025～2032年）

• 市場概要
• 抗血小板薬
• 抗凝固剤
• ベータ遮断薬
• スタチン（コレステロール低下薬）
• アトルバスタチン
• その他

投与経路による世界の心筋梗塞（MI）治療市場規模&CAGR（2025～2032年）

• 市場概要
• 経口
• 錠剤
• カプセル
• 注射
• 静脈内（IV）
• 皮下（SC）
• 経皮
• パッチ

エンドユーザーによる世界の心筋梗塞（MI）治療市場規模&CAGR（2025～2032年）

• 市場概要
• 病院
• 専門クリニック
• 外来手術センター（ASC）
• 在宅医療

世界の心筋梗塞（MI）治療市場規模&CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主要市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
• 製品ポートフォリオ分析
• セグメント別シェア分析
• 収益の前年比比較（2022～2024年）

  主要企業プロファイル

  • AstraZeneca Plc（英国）
  • Boehringer Ingelheim International GmbH（ドイツ）
  • Eli Lilly and Company（米国）
  • Amgen（米国）
  • Novartis AG（スイス）
  • Idorsia Pharmaceuticals Ltd.（スイス）
  • Faraday Pharmaceuticals（米国）
  • Immediate Therapeutics（米国）
  • Mitsubishi Chemical Group（日本）
  • Kancera（スウェーデン）
  • Bayer AG（ドイツ）
  • Recardio（米国）
  • Mesoblast Ltd.（オーストラリア）
  • Athera BIoTechnologies AB（スウェーデン）
  • Bristol Myers Squibb Co.（米国）
  • CeleCor Therapeutics（米国）
  • CHIESI Farmaceutici SpA（イタリア）
  • CSL Ltd.（オーストラリア）
  • Ever Supreme Bio Technology（台湾）

結論と推奨事項

Global Myocardial Infarction (MI) Therapeutics Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.73 billion in 2024 to USD 32.32 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The Myocardial Infarction (MI) Therapeutics Market is poised for significant growth, primarily driven by the rising incidence of coronary artery disease, the leading cause of heart attacks. With approximately 17.3 million global fatalities attributed to heart disease annually, the urgency for effective treatment options has never been higher. Factors such as an aging population, increasing rates of obesity, and chronic conditions like diabetes and hypertension are contributing to this uptick. Additionally, lifestyle choices, including poor diet and substance abuse, are escalating myocardial infarction risk. The market is further bolstered by advancements in technology, promising innovative methods for precise blockage detection and personalized treatment approaches. As effective therapies gain traction, the MI treatment market is expected to expand, presenting lucrative opportunities for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Myocardial Infarction (MI) Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Myocardial Infarction (MI) Therapeutics Market Segmental Analysis

Global Myocardial Infarction (MI) Therapeutics Market is segmented by Therapy Type, Drug Class, Route of Administration, End-User and region. Based on Therapy Type, the market is segmented into Thrombolysis, Primary Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications (used before or after surgery or intervention therapy) and Other Emerging Therapies. Based on Drug Class, the market is segmented into Antiplatelet Agents, Anticoagulants, Beta-Blockers, Statins (Cholesterol-Lowering Drugs), Atorvastatin and Others. Based on Route of Administration, the market is segmented into Oral, Tablets, Capsules, Injectable, Intravenous (IV), Subcutaneous (SC), Transdermal and Patches. Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs) and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Myocardial Infarction (MI) Therapeutics Market

The global Myocardial Infarction (MI) Therapeutics Market is expected to experience significant growth due to the increasing prevalence of heart attacks worldwide. Key factors contributing to this growth include the rising rates of coronary artery disease and lifestyle changes, which are leading to more cases of MI. Over the upcoming years, a surge in hypertension, obesity, and smoking prevalence is likely to further stimulate demand for myocardial infarction therapies. As healthcare systems adapt to address these challenges, the market is anticipated to expand, reflecting the growing need for effective treatments and interventions to manage this critical health issue.

Restraints in the Global Myocardial Infarction (MI) Therapeutics Market

The global Myocardial Infarction (MI) Therapeutics Market faces several significant constraints that may impede its growth in the coming years. Chief among these are the escalating costs associated with research and development, alongside limitations in R&D activities. Additionally, rising overall healthcare expenditures, stringent regulatory requirements, and the substantial financial investments needed for clinical trials further compound these challenges. These factors collectively create a challenging environment for companies aiming to innovate and develop effective treatments for myocardial infarction, potentially stunting market expansion and advancements in therapeutic options for patients.

Market Trends of the Global Myocardial Infarction (MI) Therapeutics Market

The Global Myocardial Infarction (MI) Therapeutics Market is increasingly influenced by the integration of nanoparticle technology, facilitating targeted drug delivery and advanced imaging techniques for cardiovascular diseases. Recent innovations in nanoparticle design and functionality are enhancing preclinical research, enabling efficient therapeutic mechanisms that address critical challenges such as low bioavailability and bioimaging inefficiencies. By focusing on specific actions against inflammation, fibrogenesis, and promoting angiogenesis, the development of nanocarrier systems is poised to revolutionize MI treatment. This trend reflects a significant shift toward precision medicine, presenting opportunities for more effective solutions in MI diagnostics and therapeutics, thus shaping the future landscape of cardiovascular care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Myocardial Infarction (MI) Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Thrombolysis
  • Streptokinase
  • Recombinant Tissue Plasminogen Activator (rtPA)
• Primary Percutaneous Coronary Intervention (PCI)
  • Balloon Angioplasty
  • Stenting (Drug-Eluting Stents, Bare-Metal Stents)
• Coronary Artery Bypass Grafting (CABG)
• Medications (used before or after surgery or intervention therapy)
• Other Emerging Therapies

Global Myocardial Infarction (MI) Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antiplatelet Agents
• Anticoagulants
• Beta-Blockers
• Statins (Cholesterol-Lowering Drugs)
• Atorvastatin
• Others

Global Myocardial Infarction (MI) Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Tablets
• Capsules
• Injectable
• Intravenous (IV)
• Subcutaneous (SC)
• Transdermal
• Patches

Global Myocardial Infarction (MI) Therapeutics Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

Global Myocardial Infarction (MI) Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Type, Drug Class, Route of Administration, End-User)
  • US
  • Canada
• Europe (Therapy Type, Drug Class, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Drug Class, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Drug Class, Route of Administration, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Drug Class, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Pharmaceuticals Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faraday Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immediate Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Chemical Group (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kancera (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recardio (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athera Biotechnologies AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CeleCor Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CHIESI Farmaceutici SpA (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ever Supreme Bio Technology (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations